Lacaba, Baby Girl N.
HRN: 20-78-99 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/31/2022
AMPICILLIN 250MG (VIAL)
07/31/2022
08/06/2022
IV
120mg
Q12
Potentially Septic Newborn
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes